GeoVax Labs, Inc., announced on Thursday that it published the results of Phase 2a clinical testing of its JS7/MVA62B AIDS vaccine, GOVX-B11, in The Journal of Infectious Diseases.
The AIDS vaccine combines a recombinant DNA vaccine with a recombinant MVA vaccine. Both components produce virus-like particles that show the HIV envelope protein, and produce antibody and cellular responses.
The clinical trial was started in 2009 and completed in 2012, and included 299 participants.
"We are encouraged with the results seen in this trial, as the vaccine is safe and predictably induces a wide variety of immune responses directed against HIV," Paul Goepfert, the study's lead investigator, said.
The study included two regimens of vaccine application. The first included priming with two doses of recombinant DNA vaccine and boosting with two doses of recombinant MVA vaccine. The other began with priming and boosting with three doses of recombinant MVA vaccine.
"I am very pleased with the reproducibility of our Phase 1 results in a larger Phase 2a trial," GeoVax Chief Scientific Officer Harriet Robinson said. "I am also encouraged by the longevity of the antibody response to Env. In the partially successful RV144 trial in Thailand, antibody responses to Env decreased by 10-fold over a six month period, and the waning of the Env-specific antibody was associated with a waning of protection. The greater durability of our antibody could indicate we will achieve more sustained protection."
The study was sponsored by the National Institutes of Health and conducted by the HIV Vaccine Trials Network.